HealthQuest picks Korea’s Lunit for first investment in Asia
Lunit raises $60.5 mn in pre-IPO investment from HealthQuest, Casdin, BrightEdge, Tybourne Capital and NSG Ventures
By Nov 24, 2021 (Gmt+09:00)
LG Chem to sell water filter business to Glenwood PE for $692 million


Kyobo Life poised to buy Japan’s SBI Group-owned savings bank


KT&G eyes overseas M&A after rejecting activist fund's offer


StockX in merger talks with Naver’s online reseller Kream


Mirae Asset to be named Korea Post’s core real estate fund operator



HealthQuest Capital, a major US healthcare-focused venture growth fund, made its first investment in Asia along with other venture capitalists by purchasing shares in Lunit Inc., South Korea’s startup developing cancer detection solutions based on artificial intelligence (AI).
Lunit said on Nov. 23 that it raised 72 billion won ($60.5 million) in pre-IPO investment from HealthQuest, Casdin Capital, BrightEdge LLC in the US, Tybourne Capital Management in Hong Kong and NSG Ventures in Singapore. HealthQuest was the largest investor spending 24 billion won. In South Korea, Naver Corp. joined the funding as a strategic investor.
The startup drew an investment of 30 billion won four months ago from Guardant Health Inc., a leading precision oncology company.
“It was HealthQuest’s first investment in Asia,” Lunit’s CEO Suh Beom-seok told The Korea Economic Daily. “They chose Lunit even as there are so many promising bio venture companies in the US. That means our products are competitive enough.”
TO BOOST SUCCESS IN GLOBAL MARKETS
HealthQuest manages over $925 million of capital and is invested in a portfolio of companies diversified by healthcare sector and location with a focus on the US. The private asset firm has partnered with global pharmaceutical giants such as Johnson & Johnson, Merck & Co. Inc. and Pfizer Inc.

“HealthQuest’s key limited partners (LPs) are major hospitals in the US,” Suh said. BrightEdge is the American Cancer Society's donor-funded, philanthropic venture capital fund.
The investors are expected to help Lunit thrive globally, especially in the US since they have strong networks in the world’s top healthcare market. It is essential to cooperate with major hospitals and insurers for the success of the startup’s lung disease and breast cancer diagnosis solutions.
Lunit, founded in 2014 by six members of a hip-hop club at the Korea Advanced Institute of Science & Technology (KAIST), has been focusing on overseas markets since the company’s early stage.
Write to Jae-young Han at jyhan@hankyung.com
Jongwoo Cheon edited this article.
-
-
BiotechJW Bioscience in pancreatic cancer biomarker deal with Immunovia
Sep 15, 2021 (Gmt+09:00)
1 Min read -
BiotechKorea’s bio startup Voronoi inks $324 million deal with Brickell Biotech
Sep 02, 2021 (Gmt+09:00)
1 Min read -
COVID-19 vaccineSamsung Biologics gears up to produce mRNA drug substance
Sep 01, 2021 (Gmt+09:00)
3 Min read -
BiotechLegoChem’s biotech platform drives 28% share price spike over last month
Jul 07, 2021 (Gmt+09:00)
3 Min read